作者
V Guarneri, MV Dieci, G Bisagni, A Frassoldati, GV Bianchi, GL De Salvo, E Orvieto, L Urso, T Pascual, L Paré, P Galván, M Ambroggi, CA Giorgi, G Moretti, G Griguolo, R Vicini, A Prat, PF Conte
发表日期
2019/6/1
期刊
Annals of Oncology
卷号
30
期号
6
页码范围
921-926
出版商
Elsevier
简介
Background
In human epidermal growth factor receptor 2 (HER2+) breast cancers, neoadjuvant trials of chemotherapy plus anti-HER2 treatment consistently showed lower pathologic complete response (pCR) rates in hormone receptor (HR) positive versus negative tumors. The PerELISA study was aimed to evaluate the efficacy of a de-escalated, chemotherapy-free neoadjuvant regimen in HR+/HER2+ breast cancer patients selected on the basis of Ki67 inhibition after 2-week letrozole.
Patients and methods
PerELISA is a phase II, multicentric study for postmenopausal patients with HR+/HER2+ operable breast cancer. Patients received 2-week letrozole, and then underwent re-biopsy for Ki67 evaluation. Patients classified as molecular responders (Ki67 relative reduction >20% from baseline) continued letrozole and started trastuzumab-pertuzumab for five cycles. Patients classified as molecular non-responders …
学术搜索中的文章
V Guarneri, MV Dieci, G Bisagni, A Frassoldati… - Annals of Oncology, 2019